Clinical Trial Update: A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03) [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating Precemtabart Tocentecan with or without Bevacizumab versus Trifluridine/Tipiracil plus Bevacizumab in previously treated metas…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Precemtabart Tocentecan
• trifluridine/tipiracil (trifluridine/tipiracil)

Snippet

Sponsor: EMD Serono Research & Development Institute, Inc. | Conditions: Metastatic Colorectal Cancer | Phase 3 | Status: NOT_YET_RECRUITING